Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates

Bradley Doebbeling, M. A. Pfaller, M. J. Bale, R. P. Wenzel

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The in vitro activity of sparfloxacin (CI-978, AT-4140), a new quinolone which is active against gram-negative and gram-positive bacteria, and nine other broad-spectrum antibiotics was tested against 128 gram-negative nosocomial bloodstream isolates from separate patients. Sparfloxacin and ciprofloxacin were among the most potent antibiotics against Escherichia coli (n=40), Enterobacter cloacae (n=18), Klebsiella oxytoca (n=13), and Klebsiella pneumoniae (n=19), with MIC90 values of ≤ 0.25 μg/ml. Ciprofloxacin was slightly more potent than sparfloxacin against Serratia marcescens (n=14), the MIC90 values being 0.25 and 1.0 μg/ml respectively, although all strains were susceptible to both agents. Sparfloxacin was slightly less potent than ciprofloxacin against Pseudomonas aeruginosa (n=24), the MIC90 values being 4.0 and 0.5 μg/ml respectively. Overall, the in vitro activity of sparfloxacin compared favorably with that of ciprofloxacin and the other broad spectrum agents tested against nosocomial gram-negative bloodstream isolates.

Original languageEnglish (US)
Pages (from-to)298-301
Number of pages4
JournalEuropean Journal of Clinical Microbiology & Infectious Diseases
Volume9
Issue number4
DOIs
StatePublished - Apr 1990
Externally publishedYes

Fingerprint

Quinolones
Ciprofloxacin
Klebsiella oxytoca
Anti-Bacterial Agents
Enterobacter cloacae
Serratia marcescens
Klebsiella pneumoniae
Gram-Positive Bacteria
In Vitro Techniques
sparfloxacin
Pseudomonas aeruginosa
Escherichia coli

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Cite this

@article{acbaf1843e89469daa94f9d5887e9fa7,
title = "Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates",
abstract = "The in vitro activity of sparfloxacin (CI-978, AT-4140), a new quinolone which is active against gram-negative and gram-positive bacteria, and nine other broad-spectrum antibiotics was tested against 128 gram-negative nosocomial bloodstream isolates from separate patients. Sparfloxacin and ciprofloxacin were among the most potent antibiotics against Escherichia coli (n=40), Enterobacter cloacae (n=18), Klebsiella oxytoca (n=13), and Klebsiella pneumoniae (n=19), with MIC90 values of ≤ 0.25 μg/ml. Ciprofloxacin was slightly more potent than sparfloxacin against Serratia marcescens (n=14), the MIC90 values being 0.25 and 1.0 μg/ml respectively, although all strains were susceptible to both agents. Sparfloxacin was slightly less potent than ciprofloxacin against Pseudomonas aeruginosa (n=24), the MIC90 values being 4.0 and 0.5 μg/ml respectively. Overall, the in vitro activity of sparfloxacin compared favorably with that of ciprofloxacin and the other broad spectrum agents tested against nosocomial gram-negative bloodstream isolates.",
author = "Bradley Doebbeling and Pfaller, {M. A.} and Bale, {M. J.} and Wenzel, {R. P.}",
year = "1990",
month = "4",
doi = "10.1007/BF01968067",
language = "English (US)",
volume = "9",
pages = "298--301",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolates

AU - Doebbeling, Bradley

AU - Pfaller, M. A.

AU - Bale, M. J.

AU - Wenzel, R. P.

PY - 1990/4

Y1 - 1990/4

N2 - The in vitro activity of sparfloxacin (CI-978, AT-4140), a new quinolone which is active against gram-negative and gram-positive bacteria, and nine other broad-spectrum antibiotics was tested against 128 gram-negative nosocomial bloodstream isolates from separate patients. Sparfloxacin and ciprofloxacin were among the most potent antibiotics against Escherichia coli (n=40), Enterobacter cloacae (n=18), Klebsiella oxytoca (n=13), and Klebsiella pneumoniae (n=19), with MIC90 values of ≤ 0.25 μg/ml. Ciprofloxacin was slightly more potent than sparfloxacin against Serratia marcescens (n=14), the MIC90 values being 0.25 and 1.0 μg/ml respectively, although all strains were susceptible to both agents. Sparfloxacin was slightly less potent than ciprofloxacin against Pseudomonas aeruginosa (n=24), the MIC90 values being 4.0 and 0.5 μg/ml respectively. Overall, the in vitro activity of sparfloxacin compared favorably with that of ciprofloxacin and the other broad spectrum agents tested against nosocomial gram-negative bloodstream isolates.

AB - The in vitro activity of sparfloxacin (CI-978, AT-4140), a new quinolone which is active against gram-negative and gram-positive bacteria, and nine other broad-spectrum antibiotics was tested against 128 gram-negative nosocomial bloodstream isolates from separate patients. Sparfloxacin and ciprofloxacin were among the most potent antibiotics against Escherichia coli (n=40), Enterobacter cloacae (n=18), Klebsiella oxytoca (n=13), and Klebsiella pneumoniae (n=19), with MIC90 values of ≤ 0.25 μg/ml. Ciprofloxacin was slightly more potent than sparfloxacin against Serratia marcescens (n=14), the MIC90 values being 0.25 and 1.0 μg/ml respectively, although all strains were susceptible to both agents. Sparfloxacin was slightly less potent than ciprofloxacin against Pseudomonas aeruginosa (n=24), the MIC90 values being 4.0 and 0.5 μg/ml respectively. Overall, the in vitro activity of sparfloxacin compared favorably with that of ciprofloxacin and the other broad spectrum agents tested against nosocomial gram-negative bloodstream isolates.

UR - http://www.scopus.com/inward/record.url?scp=0025253471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025253471&partnerID=8YFLogxK

U2 - 10.1007/BF01968067

DO - 10.1007/BF01968067

M3 - Article

VL - 9

SP - 298

EP - 301

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 4

ER -